Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of rapid progressors in HIV infection as an extreme phenotype.
Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord. Olson AD, et al. Among authors: gill j. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):15-21. doi: 10.1097/QAI.0000000000000240. J Acquir Immune Defic Syndr. 2014. PMID: 24872130 Free PMC article.
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort Collaboration. Chêne G, et al. Among authors: gill j. Lancet. 2003 Aug 30;362(9385):679-86. doi: 10.1016/s0140-6736(03)14229-8. Lancet. 2003. PMID: 12957089
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003.
Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jørgensen LB, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kücherer C, Poggensee G, Ortiz M, de Mendoza C, Gill J, Fleury H, Porter K; CASCADE Collaboration. Masquelier B, et al. Among authors: gill j. J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):505-11. doi: 10.1097/01.qai.0000186361.42834.61. J Acquir Immune Defic Syndr. 2005. PMID: 16284524
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
When To Start Consortium; Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. When To Start Consortium, et al. Among authors: gill j. Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Lancet. 2009. PMID: 19361855 Free PMC article. Review.
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.
Antiretroviral Therapy Cohort Collaboration; Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Antiretroviral Therapy Cohort Collaboration, et al. Among authors: gill j. Int J Epidemiol. 2009 Dec;38(6):1624-33. doi: 10.1093/ije/dyp306. Epub 2009 Oct 9. Int J Epidemiol. 2009. PMID: 19820106 Free PMC article.
Interleukin-2 therapy in patients with HIV infection.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee; Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. INSIGHT-ESPRIT Study Group, et al. N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175. N Engl J Med. 2009. PMID: 19828532 Free PMC article. Clinical Trial.
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients; Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, et al. Among authors: gill j. Lancet. 2010 Jul 31;376(9738):340-5. doi: 10.1016/S0140-6736(10)60932-4. Epub 2010 Jul 15. Lancet. 2010. PMID: 20638118 Free PMC article.
3,228 results